|Day Low/High||164.07 / 167.99|
|52 Wk Low/High||90.14 / 196.00|
Folks are anxious, dying to be bullish yet also curbing their enthusiasm.
It may not be the likeliest of scenarios, but if Gary Johnson becomes president of the United States, investors might want to shift some money around. Here's how.
'Brexit' will be Cramer's focus, along with company earnings and Fed Chair Janet Yellen's congressional testimony.
Cramer says American Tower is a buy and is hesitant on B&G Foods.
As more states consider legalizing the drug for recreational use, forward-thinking investors are wondering how to profit.
Cramer says Time Warner is a good stock but you should sell Interoil.
How does Cramer know that investors are getting careless? Because they see takeovers everywhere.
Weed has gone from a taboo substance to a multi-billion-dollar bonanza. The growth of the marijuana sector has created opportunities for investors. Here are four to watch.
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Investors choosing among the hundreds of cannabis businesses are often caught in a conundrum as to whether medical companies are a safer investment compared to recreational businesses.
Companies are seeking options for mainstream investors to get high gains. Americans can invest in multiple businesses traded publicly on the Nasdaq or take a private investment approach.
The medical marijuana business should rack up smoking gains. We've pinpointed the three stocks that will benefit the most.
Cramer says to wait on GW Pharmaceuticals but he likes Ashland's fundamentals.
Cramer says the Federal Reserve took a 'common sense' approach to interest rates by only taking action when needed.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc ("GW Pharmaceuticals") (NASDAQ: GWPH)...
As the marijuana industry becomes a multibillion-dollar business, shares of cannabinoid drug company GW Pharmaceuticals are getting quite high.
GW Pharmaceuticals saw its stock price surge amid news of a successful Epidiolex clinical trial. But that high also generated buzz across pot stocks at large.
GW Pharma (GWPH) stock more than doubled in Monday's trading session after its cannabis-derived drug demonstrated positive results.
GW Pharma's positive Phase 3 results for its Epidiolex drug could have far-reaching implications for other treatments, Cramer says.
GW Pharma (GWPH) stock has more than doubled in trading on Monday after its cannabis-based drug successfully treated children with severe epilepsy.
GW Pharma says it plans to discuss the positive findings from the phase III study with the U.S. Food and Drug Administration regarding a possible approval filing.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.